SCHEMBL14722227

SCHEMBL14722227

O=C(NCCCCN1CCc2ccccc2C1)c1ccccc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.86
DRD3 P35462 5/20 0.86
HTR7 P34969 2/20 0.64
HTR1A P08908 1/20 0.64
HTR2A P28223 1/20 0.64
SLC6A4 P31645 1/20 0.64
HRH1 P35367 1/20 0.64
HTR2B P41595 1/20 0.64
PRMT5 O14744 2/20 0.62
WDR77 Q9BQA1 2/20 0.62
ACKR3 P25106 1/20 0.62
TMEM97 Q5BJF2 1/20 0.62
SIGMAR1 Q99720 1/20 0.62
NAMPT P43490 1/20 0.61
LMNA P02545 1/20 0.60
DRD1 P21728 1/20 0.59
DRD4 P21917 1/20 0.59
OPRM1 P35372 1/20 0.58
HDAC3 O15379 1/20 0.58
HDAC1 Q13547 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15835899 0.96 DRD2 (0.80) DRD2DRD3HTR7HTR1AHTR2A
SCHEMBL14720609 0.91 DRD2 (0.72) DRD2DRD3HTR7HTR1AHTR2A
SCHEMBL17306839 0.90 DRD3 (0.76) DRD2DRD3ACKR3TMEM97SIGMAR1
SCHEMBL2840972 0.88 DRD3 (0.72) DRD2DRD3HTR7HTR1AHTR2A
SCHEMBL14006041 0.86 DRD2 (0.76) DRD2DRD3HTR1AHTR2APRMT5
SCHEMBL14720483 0.86 HRH4 (0.74) DRD2DRD3HTR7DRD1DRD4
SCHEMBL14006042 0.85 DRD3 (0.70) DRD2DRD3HTR7HTR1AHTR2A
SCHEMBL17306837 0.84 DRD2 (0.67) DRD2DRD3HTR7HTR1AHTR2A
SCHEMBL14721849 0.84 DRD3 (0.79) DRD2DRD3TMEM97SIGMAR1DRD1
SCHEMBL20502177 0.84 DRD2 (0.66) DRD2DRD3HTR7HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2017-12-07 US disclosed
CN-107260726-A Composition and method for treating nerve degenerative diseases 考格尼申治疗股份有限公司 2017-10-20 CN disclosed
US-20140378460-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2014-12-25 US disclosed
CN-104053436-A Compositions and methods for treating neurodegenerative diseases COGNITION THERAPEUTICS INC 2014-09-17 CN disclosed
EP-2747768-A2 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE Cognition Therapeutics, Inc. (US) 2014-07-02 EP disclosed
WO-2013029060-A2 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378460-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, SIGMAR1 DRD2 164/4885DRD3 475/4885HTR7 184/4885
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, SIGMAR1 DRD2 164/4885DRD3 475/4885HTR7 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.